This NOFO invites R61/R33 applications that address health equity, drug costs, and access to new therapeutics or repurposed drugs for Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). Successful applications will seek to identify preferences for pharmacological treatment among racial and ethnic minority people living with AD/ADRD, assess whether cost barriers to pharmacological care exist for racial and ethnic minority people living with AD/ADRD, and quantify expenditures and health- related quality of life (HRQoL) among people interested in receiving novel or repurposed drugs for AD/ADRD. This NOFO will support a study development phase (R61) to conduct rigorous stakeholder engagement with racial and ethnic minority groups to identify, measure, and assess the demand for new and repurposed drugs, and if successful, grantees will transition to an R33 phase for implementation of rigorous modeling of costs and health-related quality of life and dissemination of model findings.